vs
Side-by-side financial comparison of Celularity Inc (CELU) and High Roller Technologies, Inc. (ROLR). Click either name above to swap in a different company.
High Roller Technologies, Inc. is the larger business by last-quarter revenue ($6.3M vs $5.3M, roughly 1.2× Celularity Inc). High Roller Technologies, Inc. runs the higher net margin — 58.4% vs -436.7%, a 495.1% gap on every dollar of revenue. On growth, High Roller Technologies, Inc. posted the faster year-over-year revenue change (-16.4% vs -43.2%).
Celularity Inc is a clinical-stage biotechnology firm that develops off-the-shelf placental-derived cell therapies and immunotherapies for treating cancer, autoimmune, and degenerative diseases. It operates primarily in the U.S. market, with product candidates covering oncology, regenerative medicine, and infectious disease segments.
S&S – Sansei Technologies is an American company known for its pneumatically powered amusement rides and roller coaster designing.
CELU vs ROLR — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | ||
|---|---|---|
| Revenue | $5.3M | $6.3M |
| Net Profit | $-23.1M | $3.7M |
| Gross Margin | 26.1% | — |
| Operating Margin | -244.1% | 1.3% |
| Net Margin | -436.7% | 58.4% |
| Revenue YoY | -43.2% | -16.4% |
| Net Profit YoY | -43.3% | 831.9% |
| EPS (diluted) | $-0.88 | $0.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $5.3M | $6.3M | ||
| Q2 25 | $5.7M | $6.9M | ||
| Q1 25 | $11.4M | $6.8M | ||
| Q4 24 | $18.1M | — | ||
| Q3 24 | $9.3M | $7.5M | ||
| Q2 24 | $12.1M | — | ||
| Q1 24 | $14.7M | — | ||
| Q4 23 | $12.1M | — |
| Q3 25 | $-23.1M | $3.7M | ||
| Q2 25 | $-24.5M | $-592.0K | ||
| Q1 25 | $-19.8M | $-3.3M | ||
| Q4 24 | $-13.3M | — | ||
| Q3 24 | $-16.1M | $-501.0K | ||
| Q2 24 | $-6.5M | — | ||
| Q1 24 | $-22.0M | — | ||
| Q4 23 | $9.5M | — |
| Q3 25 | 26.1% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | 68.9% | — | ||
| Q4 24 | 59.5% | — | ||
| Q3 24 | 58.2% | — | ||
| Q2 24 | 82.5% | — | ||
| Q1 24 | 88.8% | — | ||
| Q4 23 | 20.7% | — |
| Q3 25 | -244.1% | 1.3% | ||
| Q2 25 | -276.6% | -7.2% | ||
| Q1 25 | -91.8% | -47.4% | ||
| Q4 24 | -51.2% | — | ||
| Q3 24 | -124.0% | -6.3% | ||
| Q2 24 | -84.0% | — | ||
| Q1 24 | -50.2% | — | ||
| Q4 23 | — | — |
| Q3 25 | -436.7% | 58.4% | ||
| Q2 25 | -427.5% | -8.5% | ||
| Q1 25 | -172.9% | -48.4% | ||
| Q4 24 | -73.3% | — | ||
| Q3 24 | -173.2% | -6.7% | ||
| Q2 24 | -53.6% | — | ||
| Q1 24 | -149.9% | — | ||
| Q4 23 | 78.8% | — |
| Q3 25 | $-0.88 | $0.39 | ||
| Q2 25 | $-1.02 | $-0.07 | ||
| Q1 25 | $-0.84 | $-0.39 | ||
| Q4 24 | $-0.58 | — | ||
| Q3 24 | $-0.73 | $-0.07 | ||
| Q2 24 | $-0.30 | — | ||
| Q1 24 | $-1.03 | — | ||
| Q4 23 | $0.80 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | ||
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $120.0K | $2.7M |
| Total DebtLower is stronger | $35.7M | — |
| Stockholders' EquityBook value | $-20.1M | $6.6M |
| Total Assets | $114.2M | $16.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $120.0K | $2.7M | ||
| Q2 25 | $863.0K | $2.7M | ||
| Q1 25 | $293.0K | $3.5M | ||
| Q4 24 | $738.0K | — | ||
| Q3 24 | $133.0K | $1.3M | ||
| Q2 24 | $467.0K | — | ||
| Q1 24 | $1.9M | — | ||
| Q4 23 | $227.0K | — |
| Q3 25 | $35.7M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
| Q3 25 | $-20.1M | $6.6M | ||
| Q2 25 | $-25.5M | $2.6M | ||
| Q1 25 | $-5.5M | $2.8M | ||
| Q4 24 | $8.8M | — | ||
| Q3 24 | $17.3M | $-779.0K | ||
| Q2 24 | $27.8M | — | ||
| Q1 24 | $31.2M | — | ||
| Q4 23 | $41.0M | — |
| Q3 25 | $114.2M | $16.0M | ||
| Q2 25 | $120.3M | $12.3M | ||
| Q1 25 | $128.9M | $12.8M | ||
| Q4 24 | $132.7M | — | ||
| Q3 24 | $128.8M | $12.9M | ||
| Q2 24 | $135.5M | — | ||
| Q1 24 | $143.8M | — | ||
| Q4 23 | $143.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | ||
|---|---|---|
| Operating Cash FlowLast quarter | $-4.2M | $-78.0K |
| Free Cash FlowOCF − Capex | — | $-90.0K |
| FCF MarginFCF / Revenue | — | -1.4% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | -0.02× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-4.2M | $-78.0K | ||
| Q2 25 | $-999.0K | $-840.0K | ||
| Q1 25 | $-3.0M | $-3.6M | ||
| Q4 24 | $1.6M | — | ||
| Q3 24 | $-144.0K | — | ||
| Q2 24 | $-3.4M | — | ||
| Q1 24 | $-4.4M | — | ||
| Q4 23 | $-4.3M | — |
| Q3 25 | — | $-90.0K | ||
| Q2 25 | — | $-845.0K | ||
| Q1 25 | — | $-3.6M | ||
| Q4 24 | $1.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-3.5M | — | ||
| Q1 24 | $-4.4M | — | ||
| Q4 23 | $-4.9M | — |
| Q3 25 | — | -1.4% | ||
| Q2 25 | — | -12.2% | ||
| Q1 25 | — | -53.5% | ||
| Q4 24 | 8.3% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -28.7% | — | ||
| Q1 24 | -30.3% | — | ||
| Q4 23 | -40.6% | — |
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 0.3% | — | ||
| Q4 23 | 4.8% | — |
| Q3 25 | — | -0.02× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | -0.45× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CELU
| License Royalty And Other | $2.9M | 56% |
| Degenerative Disease | $2.2M | 42% |
ROLR
| Net Gaming Revenue | $4.9M | 77% |
| Net Revenue Noncore Services | $1.4M | 23% |